A framework to support new product introduction in national health systems
Product Adoption & Decision-Making
Supporting a Ministry of Health's decision to incorporate products into national guidelines
To guide the adoption of and decisions around new products, programs should work collaboratively with the Ministry of Health, implementing partners, and community groups.
Product Adoption & Decision-Making Checklist
Evaluate the benefits and considerations of new products using the five lenses approach (outlined in the Product Adoption and Decision-Making chapter)
Gather key information on the new product to build a case for its adoption and introduction (examples and samples included in the resources section below)
Build consensus on product adoption by engaging key stakeholders and decision makers utilizing existing forums such as technical working groups
Conduct a guidelines analysis and costing evaluation
Update national treatment guidelines based on new product decisions
Product Adoption & Decision-Making Tools and Resources
In preparing for national discussions on product adoption, sufficient information on the new product should be compiled. This section outlines critical resources and tools that should be assembled and developed for sharing with key stakeholders during the technical engagement processes.
Pediatric DRV/r (pDRV/r) Resources
Pediatric darunavir/ritonavir 120/20mg (pDRV/r) is a new fixed-dose combination of darunavir (DRV) with ritonavir for children living with HIV (CLHIV) who are at least 3 years old and weigh at least 10kg. Laurus Labs, with CHAI and Unitaid, is currently developing this product with the goal of tentative US FDA approval in the second half of 2024. These resources will support country programs to evaluate adopting pDRV/r within their own contexts.
